Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 2,866 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: NaCl Clear all
Completed Phase 3 Interventional

Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)

NCT03608397
View directory record Official record
Conditions
Cervical Dystonia
Interventions
DaxibotulinumtoxinA for injection, Placebo
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
44
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 19, 2026, 11:07 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

NCT04030455
View directory record Official record
Conditions
Laryngeal Squamous Cell Carcinoma, Stage II Laryngeal Cancer AJCC v8, Stage III Laryngeal Cancer AJCC v8
Interventions
Carboplatin, Cisplatin, Docetaxel, Pembrolizumab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 19, 2026, 11:07 PM EDT
Completed Not applicable Interventional Results available

Stimulating Language in Subacute StrokE

NCT02674490
View directory record Official record
Conditions
Stroke
Interventions
A-tDCS (1 mA), SALT, Sham
Device · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 19, 2026, 11:07 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

NCT04199689
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
9vHPV Vaccine, Placebo (Saline for Injection)
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
20 Years to 45 Years · Male only
Enrollment
6,033 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
32
States / cities
Northridge, California • Rialto, California • Simi Valley, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 19, 2026, 11:07 PM EDT
Completed Phase 2 Interventional Results available

Comparison of Loss of Resistance Techniques

NCT00638274
View directory record Official record
Conditions
Pain Relief
Interventions
Air, Saline
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Female only
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 9, 2018 · Synced Oct 19, 2026, 11:07 PM EDT
Recruiting Phase 1 Interventional

Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

NCT05285358
View directory record Official record
Conditions
Distal Bile Duct Adenocarcinoma, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Metastatic Malignant Neoplasm in the Peritoneum, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Intrahepatic Bile Duct Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Stage IVB Gallbladder Cancer AJCC v8
Interventions
Cisplatin, Gemcitabine, Nab-paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 19, 2026, 11:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults

NCT01578889
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-MAG vaccine, IL-12 pDNA adjuvant, VSV HIV gag vaccine, Placebo, Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device
Biological · Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
5
States / cities
New York, New York • Rochester, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 19, 2026, 11:07 PM EDT
Completed Phase 3 Interventional Results available

Study of Intra-articular Injections vs Placebo in Patients With Pain From Osteoarthritis of the Knee

NCT01887678
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Traumeel® / Zeel® Injectable Solution, Placebo
Drug
Lead sponsor
Biologische Heilmittel Heel GmbH
Industry
Eligibility
45 Years to 80 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
30
States / cities
Phoenix, Arizona • Tucson, Arizona • Dinuba, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Oct 19, 2026, 11:07 PM EDT
Completed Phase 2 Interventional Results available

DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis

NCT03825315
View directory record Official record
Conditions
Plantar Fasciitis
Interventions
DAXI 80 U, DAXI 120 U, Placebo
Biological · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
20
States / cities
Tucson, Arizona • Carmichael, California • Castro Valley, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 19, 2026, 11:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pilot Study to Evaluate the Efficacy and Safety of Ariva® Silver Wintergreen in Healthy Smokers

NCT01337817
View directory record Official record
Conditions
Tobacco Use Disorder, Smoking
Interventions
Ariva Silver Wintergreen, Ariva Wintergreen
Other
Lead sponsor
Star Scientific, Inc
Industry
Eligibility
23 Years to 72 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Martinsburg, West Virginia
Source: ClinicalTrials.gov public record
Updated Oct 24, 2014 · Synced Oct 19, 2026, 11:07 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection

NCT04350138
View directory record Official record
Conditions
Gonococcal Infection
Interventions
Meningococcal Group B Vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
2,606 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 19, 2026, 11:07 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Insulin and Insulin Pulses During Fasting

NCT06424015
View directory record Official record
Conditions
PreDiabetes
Interventions
Intralipid and heparin, Saline
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 19, 2026, 11:07 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Supplemental Citicoline Administration to Reduce Lung Injury Efficacy Trial (SCARLET)

NCT05881135
View directory record Official record
Conditions
COVID-19
Interventions
Citicoline, Saline/Placebo
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 19, 2026, 11:07 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

NCT05063552
View directory record Official record
Conditions
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Lip and Oral Cavity Carcinoma, Metastatic Nasal Cavity Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Pharyngeal Squamous Cell Carcinoma, Metastatic Sinonasal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Pharyngeal Squamous Cell Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
Interventions
Atezolizumab, Bevacizumab, Biospecimen Collection, Carboplatin, Cetuximab, Cisplatin, Computed Tomography, Docetaxel, Echocardiography Test, Magnetic Resonance Imaging, Positron Emission Tomography
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
172
States / cities
Little Rock, Arkansas • Dublin, California • Emeryville, California + 135 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 19, 2026, 11:07 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

NCT03136406
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Cyclophosphamide, Oxaliplatin, Capecitabine, 5-Fluorouracil, Leucovorin, nab-paclitaxel, bevacizumab, avelumab, ALT-803, aNK for Infusion, ETBX-011, GI-4000
Drug · Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 19, 2026, 11:07 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin

NCT01285609
View directory record Official record
Conditions
Lung Cancer - Non Small Cell Squamous
Interventions
Ipilimumab, Placebo, Paclitaxel, Carboplatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
33
States / cities
San Diego, California • West Haven, Connecticut • Boca Raton, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 19, 2026, 11:07 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer

NCT00217399
View directory record Official record
Conditions
Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
sorafenib tosylate, anastrozole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Oct 19, 2026, 11:07 PM EDT
Completed Early Phase 1 Interventional

Intraarticular Lumbar Joint Corticosteroid Injection(s) as a Treatment of Chronic Low Back Pain in a Selected Population

NCT01382771
View directory record Official record
Conditions
Low Back Pain
Interventions
Intra-articular corticosteroid injection, Intra-articular saline injection
Drug
Lead sponsor
University of Florida
Other
Eligibility
45 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 14, 2013 · Synced Oct 19, 2026, 11:07 PM EDT
Terminated Phase 2 Interventional Results available

Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases

NCT02490878
View directory record Official record
Conditions
Radionecrosis, Brain Metastases
Interventions
bevacizumab, corticosteroids, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
332
States / cities
Anchorage, Alaska • Arroyo Grande, California • Burbank, California + 198 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 19, 2026, 11:07 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Qualitative Research on Women With Congenital Adrenal Hyperplasia

NCT00559078
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Interview
Other
Lead sponsor
Lehigh University
Other
Eligibility
25 Years to 55 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 9, 2009 · Synced Oct 19, 2026, 11:07 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Pgp Transporter and CNS Biodistribution of Ondansetron in Healthy Volunteers

NCT03809234
View directory record Official record
Conditions
Neuropathic Pain
Interventions
Ondansetron 8mg with Saline & Tariquidar, Ondansetron 16mg with Saline & Tariquidar
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 19, 2026, 11:07 PM EDT
Completed Phase 3 Interventional Results available

Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

NCT06729606
View directory record Official record
Conditions
Covid19
Interventions
Aviptadil, Aviptadil Placebo, Corticosteroid
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 19, 2026, 11:07 PM EDT
Completed Early Phase 1 Interventional

Intravenous Plasma Treatment for Parkinson's Disease

NCT04202757
View directory record Official record
Conditions
Idiopathic Parkinson Disease
Interventions
[21CFR640.30] Plasma from 18 - 25 year old volunteer donors, Saline
Biological · Other
Lead sponsor
The Neurology Center
Other
Eligibility
45 Years to 90 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 19, 2026, 11:07 PM EDT
Active, not recruiting Phase 2 Interventional

High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients

NCT05215327
View directory record Official record
Conditions
Immunization; Infection, Transplantation Infection, Influenza
Interventions
High Dose Quadrivalent Inactivated Influenza Vaccine, Standard Dose Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
16 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 19, 2026, 11:07 PM EDT